Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria

Antimicrob Agents Chemother. 2008 Apr;52(4):1493-5. doi: 10.1128/AAC.01367-07. Epub 2008 Feb 11.

Abstract

Eighty adults in areas of Kenya where malaria is holoendemic received presumptive treatment with atovaquone-proguanil and were followed closely. The time to the first Plasmodium falciparum parasitemia was 32 days. This prolonged prophylaxis period has implications for study design when used in malaria intervention trials and cautiously suggests clinical investigation of potential preexposure prophylaxis of malaria.

Publication types

  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antimalarials / therapeutic use*
  • Atovaquone / therapeutic use*
  • Chemoprevention
  • Humans
  • Kaplan-Meier Estimate
  • Kenya
  • Malaria Vaccines / administration & dosage
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / immunology
  • Malaria, Falciparum* / parasitology
  • Malaria, Falciparum* / prevention & control
  • Parasitemia* / drug therapy
  • Parasitemia* / immunology
  • Parasitemia* / parasitology
  • Plasmodium falciparum / drug effects
  • Plasmodium falciparum / immunology
  • Proguanil / therapeutic use*
  • Time Factors

Substances

  • Antimalarials
  • Malaria Vaccines
  • Proguanil
  • Atovaquone